|Other Names||Proto-oncogene FRAT1, Frequently rearranged in advanced T-cell lymphomas 1, FRAT-1, FRAT1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP1436b was selected from the C-term region of human FRAT1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Positively regulates the Wnt signaling pathway by stabilizing beta-catenin through the association with GSK-3. May play a role in tumor progression and collaborate with PIM1 and MYC in lymphomagenesis.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
FRAT1 belongs to the GSK-3-binding protein family. It may function in tumor progression and in lymphomagenesis.
Hagen,T., J. Biol. Chem. 281 (46), 35021-35029 (2006)Wang,Y., Br. J. Cancer 94 (5), 686-691 (2006)Hino,S., J. Biol. Chem. 278 (16), 14066-14073 (2003)
If you have any additional inquiries please email technical services at email@example.com.